{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T19:50:38Z","timestamp":1768765838269,"version":"3.49.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"S6","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1186\/1471-2334-14-s6-s16","type":"journal-article","created":{"date-parts":[[2014,9,19]],"date-time":"2014-09-19T09:03:43Z","timestamp":1411117423000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["A systematic review of Hepatitis C virus treatment uptake among people who inject drugs in the European Region"],"prefix":"10.1186","volume":"14","author":[{"given":"Jeffrey V","family":"Lazarus","sequence":"first","affiliation":[]},{"given":"Ida","family":"Sperle","sequence":"additional","affiliation":[]},{"given":"Mojca","family":"Maticic","sequence":"additional","affiliation":[]},{"given":"Lucas","family":"Wiessing","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2014,9,19]]},"reference":[{"key":"3821_CR1","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1002\/hep.26141","volume":"57","author":"HK Mohd","year":"2013","unstructured":"Mohd HK, Groeger J, Flaxman AD, Wiersma ST: Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013, 57: 1333-1342. 10.1002\/hep.26141.","journal-title":"Hepatology"},{"key":"3821_CR2","volume-title":"Guidelines for the screening, care and treatment of persons with hepatitis C infection","author":"World Health Organization","year":"2014","unstructured":"World Health Organization: Guidelines for the screening, care and treatment of persons with hepatitis C infection. 2014, Geneva, Switzerland"},{"key":"3821_CR3","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.jhep.2006.05.013","volume":"45","author":"JF Perz","year":"2006","unstructured":"Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP: The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006, 45: 529-538. 10.1016\/j.jhep.2006.05.013.","journal-title":"J Hepatol"},{"key":"3821_CR4","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","volume":"380","author":"R Lozano","year":"2012","unstructured":"Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al: Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012, 380: 2095-2128. 10.1016\/S0140-6736(12)61728-0.","journal-title":"Lancet"},{"key":"3821_CR5","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1017\/S0950268813000940","volume":"142","author":"VD Hope","year":"2014","unstructured":"Hope VD, Eramova I, Capurro D, Donoghoe MC: Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association. Epidemiol Infect. 2014, 142: 270-286. 10.1017\/S0950268813000940.","journal-title":"Epidemiol Infect"},{"key":"3821_CR6","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/1471-2334-13-181","volume":"13","author":"SJ Hahne","year":"2013","unstructured":"Hahne SJ, Veldhuijzen IK, Wiessing L, Lim TA, Salminen M, Laar M: Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening. BMC Infect Dis. 2013, 13: 181-10.1186\/1471-2334-13-181.","journal-title":"BMC Infect Dis"},{"key":"3821_CR7","volume-title":"European Drug Report 2013: Trends and development","author":"EMCDDA","year":"2013","unstructured":"EMCDDA: European Drug Report 2013: Trends and development. 2013, Lisbon, Portugal, EMCDDA"},{"issue":"Suppl 2","key":"3821_CR8","doi-asserted-by":"publisher","first-page":"S80","DOI":"10.1093\/cid\/cit306","volume":"57","author":"EJ Aspinall","year":"2013","unstructured":"Aspinall EJ, Corson S, Doyle JS, Grebely J, Hutchinson SJ, Dore GJ, et al: Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis. 2013, 57 (Suppl 2): S80-S89. 10.1093\/cid\/cit306.","journal-title":"Clin Infect Dis"},{"key":"3821_CR9","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1086\/600304","volume":"49","author":"M Hellard","year":"2009","unstructured":"Hellard M, Sacks-Davis R, Gold J: Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis. 2009, 49: 561-573. 10.1086\/600304.","journal-title":"Clin Infect Dis"},{"key":"3821_CR10","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/hep.24656","volume":"55","author":"NK Martin","year":"2012","unstructured":"Martin NK, Vickerman P, Miners A, Foster GR, Hutchinson SJ, Goldberg DJ, et al: Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology. 2012, 55: 49-57. 10.1002\/hep.24656.","journal-title":"Hepatology"},{"key":"3821_CR11","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1111\/jvh.12008","volume":"19","author":"P Bruggmann","year":"2012","unstructured":"Bruggmann P: Accessing Hepatitis C patients who are difficult to reach: it is time to overcome barriers. J Viral Hepat. 2012, 19: 829-835. 10.1111\/jvh.12008.","journal-title":"J Viral Hepat"},{"issue":"Suppl 2","key":"3821_CR12","doi-asserted-by":"publisher","first-page":"S56","DOI":"10.1093\/cid\/cit271","volume":"57","author":"P Bruggmann","year":"2013","unstructured":"Bruggmann P, Litwin AH: Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all. Clin Infect Dis. 2013, 57 (Suppl 2): S56-S61. 10.1093\/cid\/cit271.","journal-title":"Clin Infect Dis"},{"issue":"Suppl 2","key":"3821_CR13","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1093\/cid\/cit263","volume":"57","author":"C Treloar","year":"2013","unstructured":"Treloar C, Rance J, Backmund M: Understanding barriers to hepatitis C virus care and stigmatization from a social perspective. Clin Infect Dis. 2013, 57 (Suppl 2): S51-S55. 10.1093\/cid\/cit263.","journal-title":"Clin Infect Dis"},{"key":"3821_CR14","doi-asserted-by":"publisher","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","volume":"6","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009, 6: e1000100-10.1371\/journal.pmed.1000100.","journal-title":"PLoS Med"},{"key":"3821_CR15","doi-asserted-by":"publisher","first-page":"e103345","DOI":"10.1371\/journal.pone.0103345","volume":"9","author":"L Wiessing","year":"2014","unstructured":"Wiessing L, Ferri M, Grady B, Kantzanou M, Sperle I, Cullen KJ, et al: Hepatitis C Virus Infection Epidemiology among People Who Inject Drugs in Europe: A Systematic Review of Data for Scaling Up Treatment and Prevention. PLoS One. 2014, 9: e103345-10.1371\/journal.pone.0103345.","journal-title":"PLoS One"},{"key":"3821_CR16","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/j.1369-1600.2009.00148.x","volume":"14","author":"N Ebner","year":"2009","unstructured":"Ebner N, Wanner C, Winklbaur B, Matzenauer C, Jachmann CA, Thau K, et al: Retention rate and side effects in a prospective trial on hepatitis C treatment with pegylated interferon alpha-2a and ribavirin in opioid-dependent patients. Addict Biol. 2009, 14: 227-237. 10.1111\/j.1369-1600.2009.00148.x.","journal-title":"Addict Biol"},{"key":"3821_CR17","volume-title":"Gastroenterol Res Pract","author":"J Moussalli","year":"2010","unstructured":"Moussalli J, Delaquaize H, Boubilley D, Lhomme JP, Merleau PJ, Sabot D, et al: Factors to improve the management of hepatitis C in drug users: an observational study in an addiction centre. Gastroenterol Res Pract. 2010"},{"key":"3821_CR18","first-page":"w13193","volume":"141","author":"A Witteck","year":"2011","unstructured":"Witteck A, Schmid P, Hensel-Koch K, Thurnheer MC, Bruggmann P, Vernazza P: Management of hepatitis C virus (HCV) infection in drug substitution programs. Swiss Med Wkly. 2011, 141: w13193-","journal-title":"Swiss Med Wkly"},{"key":"3821_CR19","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1097\/MEG.0b013e3282f479ab","volume":"20","author":"G Defossez","year":"2008","unstructured":"Defossez G, Verneau A, Ingrand I, Silvain C, Ingrand P, Beauchant M: Evaluation of the French national plan to promote screening and early management of viral hepatitis C, between 1997 and 2003: a comparative cross-sectional study in Poitou-Charentes region. Eur J Gastroenterol Hepatol. 2008, 20: 367-372. 10.1097\/MEG.0b013e3282f479ab.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"3821_CR20","volume-title":"Briefrapport Infectieziektebestrijding in de verslavingszorg in Nederland","author":"M Van Veen","year":"2009","unstructured":"Van Veen M: Briefrapport Infectieziektebestrijding in de verslavingszorg in Nederland. 2009"},{"key":"3821_CR21","volume-title":"Alimentary Pharmacology and Therapeutics","author":"M Wilkinson","year":"2009","unstructured":"Wilkinson M, Crawford V, Tippet A, Jolly F, Turton J, Sims E, et al: Community-based treatment for chronic hepatitis C in drug users: High rates of compliance with therapy despite ongoing drug use. Alimentary Pharmacology and Therapeutics. 2009, 29:"},{"key":"3821_CR22","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0399-8320(04)95008-7","volume":"28","author":"M Cournot","year":"2004","unstructured":"Cournot M, Glibert A, Castel F, Druart F, Imani K, Lauwers-Cances V, et al: Management of hepatitis C in active drugs users: experience of an addiction care hepatology unit. Gastroenterol Clin Biol. 2004, 28: 533-539. 10.1016\/S0399-8320(04)95008-7.","journal-title":"Gastroenterol Clin Biol"},{"key":"3821_CR23","first-page":"459","volume":"12","author":"G Gazdag","year":"2010","unstructured":"Gazdag G, Horvath G, Szabo O, Ungvari GS: Barriers to antiviral treatment in hepatitis C infected intravenous drug users. Neuropsychopharmacol Hung. 2010, 12: 459-462.","journal-title":"Neuropsychopharmacol Hung"},{"key":"3821_CR24","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1093\/qjmed\/94.3.153","volume":"94","author":"SL Jowett","year":"2001","unstructured":"Jowett SL, Agarwal K, Smith BC, Craig W, Hewett M, Bassendine DR, et al: Managing chronic hepatitis C acquired through intravenous drug use. QJM. 2001, 94: 153-158. 10.1093\/qjmed\/94.3.153.","journal-title":"QJM"},{"key":"3821_CR25","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1258\/ijsa.2011.010416","volume":"22","author":"J Kieran","year":"2011","unstructured":"Kieran J, Dillon A, Farrell G, Jackson A, Norris S, Mulcahy F, et al: High uptake of hepatitis C virus treatment in HIV\/hepatitis C virus co-infected patients attending an integrated HIV\/hepatitis C virus clinic. Int J STD AIDS. 2011, 22: 571-576. 10.1258\/ijsa.2011.010416.","journal-title":"Int J STD AIDS"},{"key":"3821_CR26","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/14017430601049365","volume":"13","author":"W Cullen","year":"2007","unstructured":"Cullen W, Stanley J, Langton D, Kelly Y, Bury G: Management of hepatitis C among drug users attending general practice in Ireland: baseline data from the Dublin area hepatitis C in general practice initiative. Eur J Gen Pract. 2007, 13: 5-12. 10.1080\/14017430601049365.","journal-title":"Eur J Gen Pract"},{"key":"3821_CR27","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.gastrohep.2009.07.008","volume":"32","author":"FM Hernandez","year":"2009","unstructured":"Hernandez FM, Rodriguez San Roman JL, Martin Suarez JM, Pena-Lopez MJ: [Acute hepatitis due to hepatitis C virus infection in the adult population]. Gastroenterol Hepatol. 2009, 32: 677-680. 10.1016\/j.gastrohep.2009.07.008.","journal-title":"Gastroenterol Hepatol"},{"key":"3821_CR28","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4321\/S1130-01082012000100005","volume":"104","author":"R Perez-Alvarez","year":"2012","unstructured":"Perez-Alvarez R, Garcia-Samaniego J, Sola R, Perez-Lopez R, Barcena R, Planas R, et al: Acute hepatitis C in Spain: a retrospective study of 131 cases. Rev Esp Enferm Dig. 2012, 104: 21-28. 10.4321\/S1130-01082012000100005.","journal-title":"Rev Esp Enferm Dig"},{"key":"3821_CR29","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.drugalcdep.2009.04.002","volume":"104","author":"V Perut","year":"2009","unstructured":"Perut V, Labalette C, Sogni P, Ferrand I, Salmon-Ceron D, Vidal-Trecan G: Access to care of patients with chronic hepatitis C virus infection in a university hospital: Is opioid dependence a limiting condition?. Drug Alcohol Depend. 2009, 104: 78-83. 10.1016\/j.drugalcdep.2009.04.002.","journal-title":"Drug Alcohol Depend"},{"key":"3821_CR30","doi-asserted-by":"publisher","first-page":"815","DOI":"10.3851\/IMP1831","volume":"16","author":"T Reiberger","year":"2011","unstructured":"Reiberger T, Obermeier M, Payer BA, Baumgarten A, Weitner L, Moll A, et al: Considerable under-treatment of chronic HCV infection in HIV patients despite acceptable sustained virological response rates in a real-life setting. Antivir Ther. 2011, 16: 815-824. 10.3851\/IMP1831.","journal-title":"Antivir Ther"},{"key":"3821_CR31","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1053\/jhep.2001.25882","volume":"34","author":"M Backmund","year":"2001","unstructured":"Backmund M, Meyer K, Von ZM, Eichenlaub D: Treatment of hepatitis C infection in injection drug users. Hepatology. 2001, 34: 188-193.","journal-title":"Hepatology"},{"key":"3821_CR32","first-page":"1091","volume":"26","author":"V Grando-Lemaire","year":"2002","unstructured":"Grando-Lemaire V, Goisset P, Sorge F, Trinchet JC, Castera L, Roulot D, et al: [Hepatitis C virus screening in drug users in an addiction out-patient unit]. Gastroenterol Clin Biol. 2002, 26: 1091-1096.","journal-title":"Gastroenterol Clin Biol"},{"key":"3821_CR33","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/j.1360-0443.2006.01698.x","volume":"102","author":"V Guadagnino","year":"2007","unstructured":"Guadagnino V, Trotta MP, Montesano F, Babudieri S, Caroleo B, Armignacco O, et al: Effectiveness of a multi-disciplinary standardized management model in the treatment of chronic hepatitis C in drug addicts engaged in detoxification programmes. Addiction. 2007, 102: 423-431. 10.1111\/j.1360-0443.2006.01698.x.","journal-title":"Addiction"},{"key":"3821_CR34","first-page":"316","volume":"101","author":"PA McCormick","year":"2008","unstructured":"McCormick PA, Keavney M, O'Toole S, Moloney J: Methadone and HCV treatment. Ir Med J. 2008, 101: 316-317.","journal-title":"Ir Med J"},{"key":"3821_CR35","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.drugalcdep.2010.01.009","volume":"109","author":"B Schulte","year":"2010","unstructured":"Schulte B, Schutt S, Brack J, Isernhagen K, Deibler P, Dilg C, et al: Successful treatment of chronic hepatitis C virus infection in severely opioid-dependent patients under heroin maintenance. Drug Alcohol Depend. 2010, 109: 248-251. 10.1016\/j.drugalcdep.2010.01.009.","journal-title":"Drug Alcohol Depend"},{"key":"3821_CR36","doi-asserted-by":"crossref","unstructured":"Crespo J, Garcia F, Castro B, Pons F: Chronic hepatitis (HCV) among intravenous drug users (IDU); reasons for not initiating the antiviral treatment. [Spanish]. Adicciones. 2001, 13 (36):","DOI":"10.20882\/adicciones.554"},{"key":"3821_CR37","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jhep.2004.11.018","volume":"42","author":"B Broers","year":"2005","unstructured":"Broers B, Helbling B, Francois A, Schmid P, Chuard C, Hadengue A, et al: Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C. J Hepatol. 2005, 42: 323-328. 10.1016\/j.jhep.2004.11.018.","journal-title":"J Hepatol"},{"key":"3821_CR38","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/j.1365-2036.2008.03872.x","volume":"29","author":"K Jack","year":"2009","unstructured":"Jack K, Willott S, Manners J, Varnam MA, Thomson BJ: Clinical trial: a primary-care-based model for the delivery of anti-viral treatment to injecting drug users infected with hepatitis C. Aliment Pharmacol Ther. 2009, 29: 38-45. 10.1111\/j.1365-2036.2008.03872.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"3821_CR39","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.4045\/tidsskr.09.33690","volume":"129","author":"O Kristensen","year":"2009","unstructured":"Kristensen O, Sundoy A, Skeie K, Vederhus JK, Oye I, Opsal A, et al: [Short-term treatment of Hepatitis C in heroin-dependent patients]. Tidsskr Nor Laegeforen. 2009, 129: 1639-1642.","journal-title":"Tidsskr Nor Laegeforen"},{"key":"3821_CR40","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/MEG.0b013e328340c451","volume":"23","author":"CE Lindenburg","year":"2011","unstructured":"Lindenburg CE, Lambers FA, Urbanus AT, Schinkel J, Jansen PL, Krol A, et al: Hepatitis C testing and treatment among active drug users in Amsterdam: results from the DUTCH-C project. Eur J Gastroenterol Hepatol. 2011, 23: 23-31. 10.1097\/MEG.0b013e328340c451.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"3821_CR41","volume-title":"Global policy report on the prevention and control of viral hepatitis","author":"World Health Organization","year":"2013","unstructured":"World Health Organization: Global policy report on the prevention and control of viral hepatitis. 2013"},{"key":"3821_CR42","volume-title":"Global Community Hepatitis Policy Report","author":"World Hepatitis Alliance","year":"2014","unstructured":"World Hepatitis Alliance: Global Community Hepatitis Policy Report. 2014"},{"key":"3821_CR43","doi-asserted-by":"crossref","unstructured":"EASL International Consensus Conference on Hepatitis C. Paris, 26-28, February 1999, Consensus Statement. European Association for the Study of the Liver. J Hepatol. 1999, 30: 956-961.","DOI":"10.1016\/S0168-8278(99)80154-8"},{"key":"3821_CR44","doi-asserted-by":"crossref","unstructured":"EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011, 55: 245-264.","DOI":"10.1016\/j.jhep.2011.02.023"},{"key":"3821_CR45","doi-asserted-by":"crossref","unstructured":"EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2014, 60: 392-420.","DOI":"10.1016\/j.jhep.2013.11.003"},{"key":"3821_CR46","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3109\/13814788.2010.545122","volume":"17","author":"K Overbeck","year":"2011","unstructured":"Overbeck K, Bruggmann P, Helbling B: Chronic Hepatitis C virus infection in Swiss primary care practices: low case loads-high barriers to treatment?. Eur J Gen Pract. 2011, 17: 103-108. 10.3109\/13814788.2010.545122.","journal-title":"Eur J Gen Pract"},{"key":"3821_CR47","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.jhep.2010.03.015","volume":"53","author":"A John-Baptiste","year":"2010","unstructured":"John-Baptiste A, Krahn M, Heathcote J, Laporte A, Tomlinson G: The natural history of hepatitis C infection acquired through injection drug use: meta-analysis and meta-regression. J Hepatol. 2010, 53: 245-251. 10.1016\/j.jhep.2010.03.015.","journal-title":"J Hepatol"},{"key":"3821_CR48","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1053\/j.gastro.2009.09.019","volume":"138","author":"GJ Dore","year":"2010","unstructured":"Dore GJ, Hellard M, Matthews GV, Grebely J, Haber PS, Petoumenos K, et al: Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology. 2010, 138: 123-135. 10.1053\/j.gastro.2009.09.019.","journal-title":"Gastroenterology"},{"key":"3821_CR49","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1111\/j.1478-3231.2008.01958.x","volume":"29","author":"G Alvarez-Uria","year":"2009","unstructured":"Alvarez-Uria G, Day JN, Nasir AJ, Russell SK, Vilar FJ: Factors associated with treatment failure of patients with psychiatric diseases and injecting drug users in the treatment of genotype 2 or 3 hepatitis C chronic infection. Liver Int. 2009, 29: 1051-1055. 10.1111\/j.1478-3231.2008.01958.x.","journal-title":"Liver Int"},{"key":"3821_CR50","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1097\/MEG.0b013e328338d9aa","volume":"22","author":"P Melin","year":"2010","unstructured":"Melin P, Chousterman M, Fontanges T, Ouzan D, Rotily M, Lang JP, et al: Effectiveness of chronic hepatitis C treatment in drug users in routine clinical practice: results of a prospective cohort study. Eur J Gastroenterol Hepatol. 2010, 22: 1050-1057. 10.1097\/MEG.0b013e328338d9aa.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"3821_CR51","volume-title":"Programmatic Update. Antiretroviral Treatment as Prevention (TASP) of HIV and TB","author":"World Health Organization","year":"2012","unstructured":"World Health Organization: Programmatic Update. Antiretroviral Treatment as Prevention (TASP) of HIV and TB. 2012, Geneva, World Health Organization"},{"key":"3821_CR52","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.drugalcdep.2010.03.006","volume":"110","author":"I Zeiler","year":"2010","unstructured":"Zeiler I, Langlands T, Murray JM, Ritter A: Optimal targeting of Hepatitis C virus treatment among injecting drug users to those not enrolled in methadone maintenance programs. Drug Alcohol Depend. 2010, 110: 228-233. 10.1016\/j.drugalcdep.2010.03.006.","journal-title":"Drug Alcohol Depend"},{"key":"3821_CR53","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.drugalcdep.2010.08.001","volume":"113","author":"P Vickerman","year":"2011","unstructured":"Vickerman P, Martin N, Hickman M: Can Hepatitis C virus treatment be used as a prevention strategy? Additional model projections for Australia and elsewhere. Drug Alcohol Depend. 2011, 113: 83-85. 10.1016\/j.drugalcdep.2010.08.001.","journal-title":"Drug Alcohol Depend"},{"key":"3821_CR54","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.jhep.2010.08.029","volume":"54","author":"NK Martin","year":"2011","unstructured":"Martin NK, Vickerman P, Foster GR, Hutchinson SJ, Goldberg DJ, Hickman M: Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol. 2011, 54: 1137-1144. 10.1016\/j.jhep.2010.08.029.","journal-title":"J Hepatol"},{"key":"3821_CR55","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/00042737-200602000-00008","volume":"18","author":"G Robaeys","year":"2006","unstructured":"Robaeys G, Van VH, Mathei C, Van RM, Bruckers L, Buntinx F: Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes. Eur J Gastroenterol Hepatol. 2006, 18: 159-166. 10.1097\/00042737-200602000-00008.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"3821_CR56","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/MEG.0b013e3283414122","volume":"23","author":"DJ Lowry","year":"2011","unstructured":"Lowry DJ, Ryan JD, Ullah N, Kelleher TB, Crowe J: Hepatitis C management: the challenge of dropout associated with male sex and injection drug use. Eur J Gastroenterol Hepatol. 2011, 23: 32-40. 10.1097\/MEG.0b013e3283414122.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"3821_CR57","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/j.1365-2893.2010.01309.x","volume":"18","author":"J Medrano","year":"2011","unstructured":"Medrano J, Resino S, Vispo E, Madejon A, Labarga P, Tuma P, et al: Hepatitis C virus (HCV) treatment uptake and changes in the prevalence of HCV genotypes in HIV\/HCV-coinfected patients. J Viral Hepat. 2011, 18: 325-330. 10.1111\/j.1365-2893.2010.01309.x.","journal-title":"J Viral Hepat"},{"key":"3821_CR58","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1159\/000049487","volume":"8","author":"O Dalgard","year":"2002","unstructured":"Dalgard O, Bjoro K, Hellum K, Myrvang B, Skaug K, Gutigard B, et al: Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up. Eur Addict Res. 2002, 8: 45-49. 10.1159\/000049487.","journal-title":"Eur Addict Res"},{"key":"3821_CR59","doi-asserted-by":"crossref","unstructured":"Fried R, Monnat M, Seidenberg A, Oppliger R, Schmid P, Herold M, et al: Swiss multicenter study evaluating the efficacy, feasibility and safety of peginterferon-alfa-2a and ribavirin in patients with chronic hepatitis C in official opiate substitution programs. Digestion. 78:","DOI":"10.1159\/000173733"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-14-S6-S16.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,15]],"date-time":"2019-08-15T05:10:28Z","timestamp":1565845828000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/1471-2334-14-S6-S16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":59,"journal-issue":{"issue":"S6","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["3821"],"URL":"https:\/\/doi.org\/10.1186\/1471-2334-14-s6-s16","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"19 September 2014","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"S16"}}